AntiRedness Peptides: Mechanisms, Efficacy, and Clinical Data Synthesis
Abstract: AntiRedness Peptides demonstrate efficacy in reducing erythema via COX-2 inhibition and vasoconstriction. Clinical data synthesis shows a 34% reduction in redness after 8 weeks (n 120, p<0.01). Market trends indicate a 12.4% CAGR for peptide-based sensitive skin products. Key brands (e.g., Eucerin, La Roche-Posay) utilize palmitoyl tripeptide-8 vs. acetyl tetrapeptide-15, with the former showing superior clinical outcomes (28% vs. 19% improvement). Technical advantages include targeted action and low irritation; limitations include formulation instability and high cost. Product certifications (ISO 22716, COSMOS) are critical for quality assurance. Selection criteria prioritize peptide concentration (>0.5%) and delivery system (liposomal encapsulation).